Adagrasib(阿达格拉西)是Mirati Therapeutics开发的一种针对KRAS G12C突变体的特异性优化口服抑制剂,用于治疗携带KRAS G12C致癌驱动突变的实体瘤,包括非小细胞肺癌(NSCLC)和结直肠癌(CRC)。2022年12月,Adagrasib获得美国FDA批准上市,用于治疗成人KRAS G12C突变的局部晚期或转移性NSCLC(已接受 ≥ 1次既往全身治疗)...
Adagrasib(阿达格拉西)是Mirati Therapeutics开发的一种针对KRAS G12C突变体的特异性优化口服抑制剂,用于治疗携带KRAS G12C致癌驱动突变的实体瘤,包括非小细胞肺癌(NSCLC)和结直肠癌(CRC)。2022年12月,Adagrasib获得美国FDA批准上市,用于治疗成人KRAS G12C突变的局部晚期或转移性NSCLC(已接受 ≥ 1次既往全身治疗)...
Beyond Docetaxel: Adagrasib Shows Promise in KRAS G12C-Mutant NSCLC Sabrina Serani July 20th 2024 Article Robert Jotte, MD, PhD, discussed findings from the phase 3 KRYSTAL-12 study evaluating adagrasib vs docetaxel in previously treated KRAS G12C-mutated non–small cell lung cancer. ...
This is to be expected, given that Class I hydrophobins contain two highly distinct protein sequence-based subdivisions (IA and IB) [25]. Each is represented amongst the hydrophobins of Table 1 as can be seen when their positions are indicated on the SA-PCA of Figure 2 established in [...